Urinary Cytology and Quantitative BTA and UBC Tests in Surveillance of Patients with pTapT1 Bladder Urothelial Carcinoma

Urology

Volumn 71, Issue 4, 2008, Pages 718-722

  Babjuk, M ^a   Soukup, V ^a   Pesl M ^a   Kostirova M ^a   Drncova E ^b   Smolova H ^a   Szakacsova M ^a   Getzenberg, R ^c   Pavlik I ^a   Dvoracek J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NA HOMOLCE HOSPITAL   (Czech Republic)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; CYTOKERATIN 18; CYTOKERATIN 8;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; CYSTOSCOPY; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; TUMOR RECURRENCE; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 41349121207     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.12.021     Document Type: Article

References (17)

1. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 Suppl 6A (2005) 4-34
2. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-475
3. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology 66 Suppl 6A (2005) 35-63
4. van Rhijn B.W.G., van der Poel H.G., and van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47 (2005) 736-748
5. Sobin L.H., and Wittekind C. UICC TNM Classification of Malignant Tumors. 5th ed. (1997), Wiley Liss, New York 187-190
6. Sanchez-Ortiz R.F., Huang W.C., Mick R., et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169 (2003) 110-115
7. Sylvester R., van der Meijden A., and Lamm D. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
8. Soloway M.S., Bruck D.S., and Kim S.S. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170 (2003) 438-441
9. Serreta V., Pomara G., Rizzo I., et al. Urinary BTA-Stat, BTA-Trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder. Eur Urol 38 (2000) 419-425
10. Sánches-Carbayo M., Herrero E., Megías J., et al. Comparative sensitivity of urinary cyfra 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 162 (1999) 1951-1956
11. Sanchez-Carbayo M., Urrutia M., Gonzalez de Buitrage J.M., et al. Utility of serial urinary markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 92 (2001) 2820-2828
12. Fernandez-Gomez J., Rodriguez-Martinez J.J., Barmadah S.E., et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol 51 (2007) 1267-1274
13. Lodde M., Mian C., Comploj E., et al. UCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 67 (2006) 950-954
14. Blumenstein B.A., Ellis W.J., and Ishak L.M. The relationship between serial measurements of the level of a bladder tumor associated antigen and the potential for recurrence. J Urol 161 (1999) 57-61
15. Lokeshwar V.B., Schroeder G.L., Selzer M.G., et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-stat tests. Cancer 95 (2002) 61-72
16. Mian C., Lodde M., Haitel A., et al. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology 55 (2000) 223-226
17. Babjuk M., Koštířová M., Mudra K., et al. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC Rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol 41 (2002) 34-39